Yükleniyor... / Loading...
This is an observational study retrospectively reviewing the records of patients in Egypt with metastatic breast cancer who were diagnosed as HER2-negative. It evaluated patients aged 18 and over whose disease had progressed after systemic therapy. The study was conducted as a non-phase observational study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Men or women ≥ 18 years of age, 2. Must have a histological, cytological, or radiological confirmed diagnosis of unresectable or/and mBC between 01 January 2017 and 31 December 2020, with at least 2 years of follow-up data unless patient's death is confirmed, 3. Diagnosed as HER2-neg (HER2 IHC 0, 1+, 2+/ISH-), regardless of hormone status, 4. Must have a report in her file with HER2 scoring with IHC/ISH or both, 5. Progressed on any systemic anti-cancer therapy (eg, ET, chemotherapy, CDK4/6i, targeted therapies other than anti-HER2, or immunotherapy) in the metastatic setting. 6. Due to the retrospective nature of the study a waiver grant of the consent will be requested from the IRB/IEC for the study participants, if waiver not granted Patient or next of kin/legal representative (for deceased patients at study entry) willing and able to provide written informed consent according to the local regulations. Exclusion Criteria: * Records of patients who meet any of the following criteria will be excluded: 1. History of other malignancies than mBC, 2. Historical HER2 status of IHC 2+/ISH+ or 3+, or HER2 amplified.